Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid
receptor and functional expression of the cloned cDNA. Nature 346:561– 564
McKallip RJ, Jia WT, Schlomer J, Warren JW, Nagarkatti PS, Nagarkatti M (2006)
Cannabidiol-induced apoptosis in human leukemia cells: a novel role of cannabidiol in the
regulation of p22(phox) and Nox4 expression. Mol Pharmacol 70:897– 908
Mechoulam R, Lander N, Varkony TH, Kimmel I, Becker O, Ben Zvi, Edery H, Porath G (1980)
Stereochemical requirements for cannabinoid activity. J Med Chem 23:1068– 1072
Mechoulam R, Feigenbaum JJ, Lander N, Segal M, Järbe TUC, Hiltunen AJ, Consroe P (1988)
Enantiomeric cannabinoids—stereospecificity of psychotropic activity. Experientia 44:762– 764
Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for
cannabinoids. Nature 365:61– 65
Munson AE, Harris LS, Friedman MA, Dewey WL, Carchman RA (1975) Anti-neoplastic activity
of cannabinoids. J Nat Cancer Instit 55:587– 602
Onaivi ES, Ishiguro H, Gong JP, Patel S, Perchuk A, Meozzi PA, Myers L, Mora Z, Tagliaferro P,
Gardner E, Brusco A, Akinshola BE, Liu QR, Hope B, Iwasaki S, Arinami T, Teasenfitz L,
Uhl GR (2006) Discovery of the presence and functional expression of cannabinoid CB2
receptors in brain. Ann N Y Acad Sci 1074:514– 536
O’Sullivan SE (2007) Cannabinoids go nuclear: evidence for activation of peroxisome
proliferator-activated receptors. Br J Pharmacol 152:576– 582
Oz M (2006) Receptor-independent effects of endocannabinoids on ion channels. Curr Pharm
Design 12:227– 239
Parker LA, Kwiatkowska M, Burton P, Mechoulam R (2004) Effect of cannabinoids on
lithium-induced vomiting in theSuncus murinus(house musk shrew). Psychopharmacology
171:156– 161
Parker LA, Rana SA, Limebeer CL (2008) Conditioned nausea in rats: assessment by conditioned
disgust reactions, rather than conditioned taste avoidance. Can J Exp Psychol 62:198– 209
Perez J, Ribera MV (2008) Managing neuropathic pain with Sativex®: a review of its pros and
cons. Expert Opin Pharmacother 9:1189– 1195
Pertwee RG (1988) The central neuropharmacology of psychotropic cannabinoids. Pharmacol
Ther 36:189– 261
Pertwee RG (1997) Pharmacology of cannabinoid CB 1 and CB 2 receptors. Pharmacol Ther
74:129– 180
Pertwee RG (2001) Cannabinoid receptors and pain. Prog Neurobiol 63:569– 611
Pertwee RG (2004a) The pharmacology and therapeutic potential of cannabidiol. In: Di Marzo V
(ed) Cannabinoids. Kluwer Academic/Plenum Publishers, New York, pp 32– 83
Pertwee RG (2004b) Pharmacological and therapeutic targets forD^9 -tetrahydrocannabinol and
cannabidiol. Euphytica 140:73– 82
Pertwee RG (2005) Pharmacological actions of cannabinoids. In: Pertwee RG (ed) cannabinoids.
Springer-Verlag, Heidelberg, pp 1– 51
Pertwee RG (2007) Cannabinoids and multiple sclerosis. Mol Neurobiol 36:45– 59
Pertwee RG (2008) The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids:
D^9 -tetrahydrocannabinol, cannabidiol and D^9 -tetrahydrocannabivarin. Br J Pharmacol
153:199– 215
Pertwee RG (2009) Emerging strategies for exploiting cannabinoid receptor agonists as medicines.
Br J Pharmacol 156:397– 411
Pertwee RG (2010) Receptors and channels targeted by synthetic cannabinoid receptor agonists
and antagonists. Curr Med Chem 17:1360– 1381
Pertwee RG (2015) Endocannabinoids and their pharmacological actions. In: Pertwee RG
(ed) Endocannabinoids. Springer-Verlag, Heidelberg, pp 1– 37
Pertwee RG, Ross RA (2002) Cannabinoid receptors and their ligands. Prostaglandins Leukot
Essent Fatty Acids 66:101–121. Review
Pertwee RG, Cascio MG (2014) Known pharmacological actions of delta-9-tetrahydrocannabinol
and of four other chemical constituents of cannabis that activate cannabinoid receptors. In:
Pertwee RG (ed) Handbook of Cannabis. Oxford University Press, Oxford, pp 115– 136
9 The Pharmacology and Therapeutic Potential of Plant Cannabinoids 223